University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln

Uniformed Services University of the Health
Sciences

U.S. Department of Defense

2011

Accelerated lymphocyte reconstitution and long-term recovery after transplantation of lentiviral-transduced rhesus CD34⁺ cells mobilized by G-CSF and plerixafor

Naoya Uchida
National Institutes of Health

Aylin Bonifacino
National Institutes of Health

Allen E. Krouse
National Institutes of Health

Mark E. Metzger
National Institutes of Health

Gyorgy Csako
National Institutes of Health

Follow this page for additional works that <https://digitalcommons.unl.edu/usuhs>

Part of the [Medicine and Health Sciences Commons](#)

Uchida, Naoya; Bonifacino, Aylin; Krouse, Allen E.; Metzger, Mark E.; Csako, Gyorgy; Lee-Stroka, Agnes; Fasano, Ross M.; Leitman, Susan F.; Mattapallil, Joseph J.; Hsieh, Matthew M.; Tisdale, John F.; and Donahue, Robert E., "Accelerated lymphocyte reconstitution and long-term recovery after transplantation of lentiviral-transduced rhesus CD34⁺ cells mobilized by G-CSF and plerixafor" (2011). *Uniformed Services University of the Health Sciences*. 42.
<https://digitalcommons.unl.edu/usuhs/42>

This Article is brought to you for free and open access by the U.S. Department of Defense at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Uniformed Services University of the Health Sciences by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.

Authors

Naoya Uchida, Aylin Bonifacino, Allen E. Krouse, Mark E. Metzger, Gyorgy Csako, Agnes Lee-Stroka, Ross M. Fasano, Susan F. Leitman, Joseph J. Mattapallil, Matthew M. Hsieh, John F. Tisdale, and Robert E. Donahue

Accelerated lymphocyte reconstitution and long-term recovery after transplantation of lentiviral-transduced rhesus CD34⁺ cells mobilized by G-CSF and plerixafor

Naoya Uchida^a, Aylin Bonifacino^b, Allen E. Krouse^b, Mark E. Metzger^b, Gyorgy Csako^c, Agnes Lee-Stroka^d, Ross M. Fasano^d, Susan F. Leitman^d, Joseph J. Mattapallil^e, Matthew M. Hsieh^a, John F. Tisdale^a, and Robert E. Donahue^b

^aMolecular and Clinical Hematology Branch, National Heart Lung and Blood Institute/National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Md., USA; ^bHematology Branch, National Heart Lung and Blood Institute, National Institutes of Health, Rockville, Md., USA; ^cDepartment of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Md., USA; ^dDepartment of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Md., USA; ^eDepartment of Microbiology and Immunology, Uniformed Services University of Health Sciences, Bethesda, Md., USA

(Received 4 March 2011; revised 6 April 2011; accepted 7 April 2011)

Objective. Granulocyte colony-stimulating factor (G-CSF) in combination with plerixafor produces significant mobilization of CD34⁺ cells in rhesus macaques. We sought to evaluate whether these CD34⁺ cells can stably reconstitute blood cells with lentiviral gene marking.

Materials and Methods. We performed hematopoietic stem cell transplantation using G-CSF and plerixafor-mobilized rhesus CD34⁺ cells transduced with a lentiviral vector, and these data were compared with those of G-CSF and stem cell factor mobilization.

Results. G-CSF and plerixafor mobilization resulted in CD34⁺ cell yields that were twofold higher than yields with G-CSF and stem cell factor. CD123 (interleukin-3 receptor) expression was greater in G-CSF and plerixafor-mobilized CD34⁺ cells when compared to G-CSF alone. Animals transplanted with G-CSF and plerixafor-mobilized cells showed engraftment of all lineages, similar to animals who received G-CSF and stem cell factor—mobilized grafts. Lymphocyte engraftment was accelerated in animals receiving the G-CSF and plerixafor-mobilized CD34⁺ cells. One animal in the G-CSF and plerixafor group developed cold agglutinin-associated skin rash during the first 3 months of rapid lymphocyte recovery. One year after transplantation, all animals had 2% to 10% transgene expression in all blood cell lineages.

Conclusions. G-CSF and plerixafor-mobilized CD34⁺ cells accelerate lymphocyte engraftment and contain hematopoietic stem cell capable of reconstituting multilineage blood cells. These findings indicate important differences to consider in plerixafor-based hematopoietic stem cell mobilization protocols in rhesus macaques. © 2011 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc.

Hematopoietic stem cell (HSC) transplantation is a therapeutic strategy for hematologic malignancies, immunodeficiency states, nonmalignant hereditary and acquired hematologic diseases, and inherited metabolic disorders. HSC transplantation is an ideal platform for delivering stem cell therapies, such as ex vivo cell manipulation for gene therapy applications [1,2]. HSCs can be mobilized

into peripheral blood and collected by apheresis. This method of peripheral blood stem cell collection is frequently used clinically for obtaining HSCs for allogeneic and autologous HSC transplantation. Currently, injection of granulocyte colony-stimulating factor (G-CSF) is the clinical standard for mobilization of human HSCs [1]. Sufficient numbers of HSCs for transplantation, however, are not obtained from all donors by G-CSF mobilization. Plerixafor (also known as AMD3100 or Mozobil) represents a new alternative agent for mobilization of HSCs. This low molecular weight, highly charged compound (C₂₈H₅₄N₈) inhibits chemokine stromal cell–derived

Offprint requests to: Robert E. Donahue, V.M.D., Hematology Branch, 5 Research Court, Building 5RC, 1B06, MSC-3315, Rockville, MD 20892; E-mail: donahuer@nhlbi.nih.gov

factor-1 α binding to CXC chemokine receptor 4 (CXCR4) to interrupt adherence of HSCs to the stem cell niche [3].

Rhesus macaques are Old World monkeys frequently used in preclinical studies evaluating HSC transplantation [4–6]. In the rhesus transplantation model, the combination of G-CSF and stem cell factor (SCF) is a standard strategy to mobilize CD34⁺ cells in which CD34⁺ cell numbers are approximately twofold greater than those achieved with use of G-CSF alone [5]. Recently, we found that G-CSF and plerixafor mobilization in rhesus macaques increased CD34⁺ cell yields approximately three- to fivefold more than mobilization with G-CSF alone, plerixafor alone, or G-CSF and SCF combined together [7]. These CD34⁺ cells demonstrated different gene expression profiles in each mobilization strategy, suggesting that the composition of mobilized CD34⁺ cells is dependent on the mobilization protocol [7].

Based on these differences, we hypothesized that G-CSF and plerixafor-mobilized CD34⁺ cells might include different hematopoietic progenitor cells when compared to previous mobilization strategies. In this study, we performed HSC transplantation using transduced rhesus CD34⁺ cells that were mobilized by G-CSF and plerixafor to evaluate whether these CD34⁺ cells would reconstitute long-term hematopoiesis differently and to determine what kind of progenitor cells were contained in the mobilized population of CD34⁺ cells.

Materials and methods

Rhesus HSC transplantation

Rhesus HSCs were obtained after five daily injections of 10 μ g/kg recombinant human G-CSF (Amgen, Inc., Thousand Oaks, CA, USA), followed by a single injection of 1 mg/kg plerixafor (Genzyme Corporation, Cambridge, MA, USA), or five-daily injections of both 10 μ g/kg G-CSF and 200 μ g/kg SCF (Amgen, Inc.). Two to four hours after the last dose of mobilizing agent, the CD34⁺ cells were harvested by leukapheresis and immunoselection was performed as described previously [4,5]. The rhesus CD34⁺ cells were cultured in serum-free X-VIVO10 media (Lonza, Allendale, NJ, USA) containing SCF, FMS-like tyrosine kinase 3 ligand, and thrombopoietin (all at 100 ng/mL; R&D Systems, Minneapolis, MN, USA) on fibronectin CH-296–coated (RetroNectin, TaKaRa, Otsu, Shiga, Japan) cell culture flasks for 1 day. These cells were then transduced with enhanced green fluorescent protein (EGFP)–expressing lentiviral vector at multiplicity of infection 50 in the same media and cytokines for 1 day [8,9]. The rhesus macaques to be transplanted received a total of 10 Gy total body irradiation, delivered as 5 Gy daily on 2 consecutive days. The transduced CD34⁺ cells were infused into these irradiated rhesus macaques. Complete blood cell counts, cell surface markers of differentiation, and EGFP expression rates in circulating blood cells were assessed periodically for a minimum of 1 year.

Lentiviral vector preparation

We developed a chimeric HIV1-based lentiviral vector system (χ HIV vector), which included simian immunodeficiency

virus–capsid instead of HIV1-capsid, for efficient transduction of rhesus CD34⁺ cells [8]. The vesicular stomatitis virus glycoprotein pseudotyped χ HIV vector, including the EGFP-expressing cassette under the control of a murine stem cell virus–long term repeat promoter, was prepared and its titer quantitated as described previously [10,11]. The basic HIV1 vector plasmid was kindly provided by Dr. Arthur Nienhuis (St. Jude Children's Research Hospital, Memphis, TN, USA) [12,13].

Flow cytometry analysis

Transduced rhesus CD34⁺ cells were cultured for an additional 3 to 4 days in vitro and EGFP expression rates were evaluated by FACSCalibur (BD Biosciences, Franklin Lakes, NJ, USA). After transplantation, we analyzed EGFP expression and cell surface markers in rhesus peripheral blood cells and bone marrow cells using phycoerythrin (PE) or allophycocyanin (APC)-conjugated antibodies (CD3-PE, clone 10D12; CD4-PE, clone M-T466; CD8-PE, clone BW135/80; CD20-PE, clone LT20; CD33-PE, clone AC104.3E3; CD34-PE, clone 563; CD41a-PE, clone HIP8; CD56-PE, clone AF12-7H3; CD71-APC, clone L01.1; RBC, clone T3G6; mouse IgG1-PE, clone A85-1; BD Pharmingen). After immunoselection, CD34⁺ cells were assessed for purity using a mouse anti-human CD34-PE (clone 563; BD Pharmingen), for interleukin (IL)-3 receptor expression (CD123) using a mouse anti-human CD123-APC (clone 7G3; BD Pharmingen), and for CD45RA using an anti-human CD45RA-FITC (clone 5H9; BD Pharmingen).

EGFP expression on lymphocytes was determined in peripheral blood, lymph nodes, and rectal mucosa collected post-transplantation using multicolor flow cytometry. Cells were isolated from these tissues as described previously [14–16]. Freshly isolated cells were labeled with CD3-Cy7-APC, CD4-PB, CD8-Alexa700, CD45RA-ECD, CD28-Cy5PE, and/or CD95-APC for phenotypic analysis of T cells. To determine the frequency of EGFP-expressing B-cell subsets, cells were labeled with CD20-PE, CD3-Cy7APC, and IgM-Cy5PE. Labeled cells were fixed in 0.5% paraformaldehyde and analyzed on an LSR-II flow cytometer. Approximately 1 million events were collected for analysis.

Red blood cell serologic testing

Direct antiglobulin testing was performed by standard tube technique using heavy chain specific human anti-IgG and murine monoclonal anti-C3d (Ortho Clinical Diagnostics, Raritan, NJ, USA). Cold agglutinin titers were performed using serial 10-fold dilutions of serum in phosphate-buffered saline, incubated with normal human adult group O or normal rhesus macaque red blood cells (RBCs) for 24 hours at 4°C. Rhesus RBCs were tested for polyagglutination using the following lectins: Glycine soja, Arachis hypogaea, Salvia sclarea and Salvia horminum (Gamma Lectin System; Immucor/Gamma, Norcross, GA, USA).

Antibody screening of animal sera was performed by standard tube technique against a panel of human adult group O, umbilical cord group O, and rhesus macaque control RBCs at immediate spin (22°C) and antiglobulin (37°C) phases of testing, using a low ionic strength solution potentiator. Sera were treated with 0.01 M dithiothreitol to differentiate IgG from IgM reactivity. To determine if a drug-related RBC antibody was present, a 1 mg/mL solution of fluconazole in phosphate-buffered saline was incubated at 37°C for 2 hours with animal sera plus native

or papain-treated group O RBCs, with or without a fresh source of complement. After a serial washing step, anti-IgG was added to all tubes.

Determination of serum immunoglobulins

Serum IgG, IgA, and IgM levels were quantified by immunonephelometry on a Dimension Vista 1500 automated analyzer using the manufacturer's methods for human subjects (Siemens Healthcare Diagnostics, Deerfield, IL, USA).

Serum protein and immunofixation electrophoresis

For analysis of various protein fractions, all sera were electrophoresed in agarose gel by a semi-automated electrophoretic system developed for human subjects (Hydragel 7 or 15 Protein(e) gels, Hydrasys system; Sebia, Norcross, GA, USA). Gels were stained with AmidoBlack. Select specimens were further analyzed with immunofixation electrophoresis in agarose gel (Hydragel 2F or 4F; Sebia) using the same semi-automated system as for protein electrophoresis (Hydrasys) and the manufacturer's monospecific anti-human immunoglobulin antibodies. The immunofixation electrophoresis method uses a more sensitive protein stain (acid violet) for improved detection of possible paraproteins.

Statistical analysis

Statistical analyses were performed using JMP 8 software (SAS Institute Inc., Cary, NC, USA). Comparison between G-CSF and plerixafor vs. G-CSF and SCF mobilization was evaluated by Student's *t*-test. A *p* value <0.05 or 0.01 was considered significant. Standard errors of the mean are shown as error bars in all figures. For G-CSF and SCF-mobilized CD34⁺ cells, we applied the linear regression *t*-test to %EGFP data between in vitro bulk CD34⁺ cells and lymphocytes at 1, 3, and 6 months post-transplantation. The 90% confidence intervals are also included.

Results

To evaluate whether G-CSF and plerixafor-mobilized CD34⁺ cells could stably reconstitute blood cells, we performed HSC transplantation using rhesus macaque CD34⁺ cells transduced with an EGFP-expressing χ HIV vector, which was developed for efficient transduction of rhesus CD34⁺ cells [8]. First, we evaluated the number and %EGFP of immunoselected CD34⁺ cells, which were transplanted into rhesus macaques. As shown in Figure 1, G-CSF and plerixafor mobilization (*n* = 3) yielded twofold greater CD34⁺ cell numbers compared to yields observed with the G-CSF and SCF combination (*n* = 5) (*p* < 0.01). Transduction rates with the χ HIV vector, however, were fourfold lower in G-CSF and plerixafor-mobilized CD34⁺ cells when compared with G-CSF and SCF-mobilized harvests (*p* < 0.01). G-CSF and plerixafor mobilization tended to result in a lower overall number of EGFP⁺CD34⁺ cells compared to G-CSF and SCF mobilization ($9.6 \pm 0.9 \times 10^6$ vs. $2.1 \pm 0.5 \times 10^7$, respectively; not significant).

Additionally, we evaluated the composition of the CD34⁺ cell population in three different mobilizations from a single animal using cell surface analysis. Time between mobilizations was 1 month or longer. CD123⁺ (IL-3 receptor) expression has been found to vary on CD34⁺ cell subpopulations [17]. CD34⁺CD123⁺ populations were higher in CD34⁺ cells mobilized by G-CSF and plerixafor or plerixafor alone when compared with that of G-CSF alone (Fig. 2).

To determine repopulating ability, G-CSF and plerixafor-mobilized CD34⁺ cells were transduced with EGFP-expressing lentiviral vector and transplanted into 5 Gy $\times$ 2 days (total dose 10 Gy) irradiated rhesus macaques

Figure 1. G-CSF and plerixafor mobilization increased CD34⁺ cell apheresis yields. G-CSF and plerixafor mobilization (*n* = 3) yielded a twofold higher number of CD34⁺ cells, compared to that observed with G-CSF and SCF mobilization (*n* = 5) (*p* < 0.01). Transduction rates with χ HIV vector, however, were fourfold lower in G-CSF and plerixafor-mobilized CD34⁺ cells, compared to that observed for G-CSF and SCF-mobilized cells (*p* < 0.01).

Figure 2. Cell surface analysis of G-CSF and plerixafor-mobilized CD34⁺ cells. CD34⁺ cells were immunoselected from a single animal (RQ6712) and immunophenotyped with murine anti-human CD34-PE and CD123 (IL-3 receptor)-APC antibodies known to be cross-reactive with rhesus macaques. Mobilizations using the designated regimens and leukapheresis procedures were separated by at least 1 month. The percentage of CD34⁺CD123⁺ expression for each mobilization regimen is shown.

($n = 3$, Fig. 3A). Whole cultures of mobilized and immunoselected CD34⁺ cells were transduced and transplanted without sorting. Blood cell counts and transgene expression levels were followed during 1 year, and these data were compared to those of G-CSF and SCF-mobilized animals ($n = 5$) transplanted previously [8]. As shown in Figure 3B, animals transplanted with G-CSF and plerixafor-mobilized cells had similar recovery of myelocytes ($2900 \pm 700/\mu\text{L}$ vs. $3500 \pm 700/\mu\text{L}$ on day 30, not significant) and earlier recovery of lymphocytes ($3300 \pm 900/\mu\text{L}$ vs. $1200 \pm 300/\mu\text{L}$ on day 30; $p < 0.05$) compared to animals who received G-CSF and SCF-mobilized grafts. Although hemoglobin concentration and platelet counts showed a tendency toward earlier recovery in animals receiving transduced CD34⁺ cells obtained after G-CSF and plerixafor mobilization, there was no significant difference between the two groups (hemoglobin: 10.5 ± 0.3 g/dL vs. 9.9 ± 0.6 g/dL; not significant; platelet: $1.9 \pm 0.2 \times 10^5/\mu\text{L}$ vs. $1.2 \pm 0.3 \times 10^5/\mu\text{L}$ on day 30; not significant). These data suggested that G-CSF and plerixafor-mobilized CD34⁺ cells contained increased numbers of early lymphoid progenitor cells.

One year after transplantation, animals transplanted with G-CSF and plerixafor-mobilized cells showed engraftment of EGFP⁺ cells in all lineages. Transgene expression levels in peripheral blood cells were 2% to 5% in the first animal (RQ7424), 2% to 5% in the second animal (RQ7375), and 5% to 10% in the third animal (RQ7277) in all lineage cells (Fig. 4A). Multilineage marking was observed by cell surface analysis in peripheral blood cells and bone marrow cells (Fig. 4B). These data indicated that G-CSF and plerixafor-mobilized CD34⁺ cells could stably reconstitute peripheral blood in the rhesus macaque. Additionally, both naïve and memory CD4 and CD8 T cells stably expressed EGFP in peripheral and mucosal lymphoid compartments (Fig. 5A, B, and D). Likewise, both CD3⁺CD20⁺IgM⁺ and CD3⁺CD20⁺IgM[−] (includes IgG and IgA) cells expressed EGFP (Fig. 5C, E), indicating long-term

reconstitution of multiple phenotypes in both primary and secondary lymphoid tissues of rhesus macaques.

Because lymphocyte recovery was more rapid in the G-CSF and plerixafor group, we compared transgene expression levels (%EGFP) among the CD34⁺ cells present in the component (graft, in vitro) and among peripheral blood lymphocytes (repopulating cells, in vivo) at 1, 3, and 6 months post-transplantation. In G-CSF and SCF-mobilized animals, there was a significant correlation of %EGFP between the CD34⁺ cells in the component (graft) and the circulating lymphocytes at all three time points ($p < 0.01$) (Fig. 6, line of regression drawn for data from G-CSF and SCF-mobilized products, $n = 5$). Data from G-CSF and plerixafor mobilizations showed a lower ratio of %EGFP labeling of CD34⁺ cells in the component to %EGFP labeling in circulating lymphocytes at 1 and 3 months after transplantation when compared to the G-CSF and SCF-mobilized transplants. Six months after transplantation, however, the ratios were similar to those obtained in animals receiving G-CSF and SCF-mobilized CD34⁺ cells, with all points being inside 90% confidence intervals of the regression line for the G-CSF and SCF mobilized products (Fig. 6). These results suggest that in vitro transduction rates predict in vivo EGFP expression in peripheral blood lymphocytes, and also that G-CSF and plerixafor-mobilized CD34⁺ cells might include a larger proportion of early lymphoid progenitor cells when compared to G-CSF and SCF-mobilized cells.

Thirty days after transplantation, a transient skin rash developed in one of the three animals transplanted with G-CSF and plerixafor-mobilized cells (Fig. 7A). The rash resolved 79 days after transplantation (Fig. 7B). This animal (RQ7375) had the most rapid lymphocyte recovery of the three animals transplanted (Fig. 3B). Skin biopsy (day 49) showed an acanthotic epidermis with superficial dermal edema and perivascular lymphocytic infiltrates

Figure 3. G-CSF and plerixafor-mobilized cells demonstrated early lymphocyte recovery. (A) G-CSF and plerixafor-mobilized CD34⁺ cells were transduced with EGFP-expressing chimeric HIV1-based lentiviral vector, including the simian immunodeficiency virus–capsid (χHIV vector), and these cells were transplanted into lethally irradiated rhesus macaques. Blood cell counts and transgene expression levels in each lineage of peripheral blood cells were assayed for at least 1 year. (B) After transplantation of transduced CD34⁺ cells, recipients of G-CSF and plerixafor-mobilized autologous grafts (n = 3) showed engraftment of all lineage cells and accelerated recovery of lymphocytes (lymphocytes: $3300 \pm 900/\mu\text{L}$ vs. $1200 \pm 300/\mu\text{L}$ on day 30, $p < 0.05$) compared to recipients of G-CSF and SCF-mobilized grafts (n = 5). There was also a trend for an accelerated recovery of hemoglobin concentration (Hb) and platelet count (PLT), but this did not reach statistical significance.

Figure 4. G-CSF and plerixafor-mobilized cells demonstrated long-term reconstitution of peripheral blood in rhesus macaques. (A) After infusion of G-CSF and plerixafor-mobilized CD34⁺ cells transduced with EGFP-expressing lentiviral vector, EGFP expression rates in peripheral blood were evaluated for at least 1 year in three rhesus macaques. EGFP expression rates were 2% to 4% in all lineage cells in the first animal (RQ7424) at 2 years, 2% to 5% in the second animal (RQ7375) at 1½ years, and 5% to 10% in the third animal (RQ7277) at 1 year after transplantation. (B) In lineage marker analysis, all lineage cells demonstrated EGFP expression in peripheral blood cells (RQ7424 on day 503, RQ7375 on day 559, and RQ7277 on day 391) and bone marrow cells (RQ7424 on day 503, RQ7375 on day 700, and RQ7277 on day 532).

Figure 5. G-CSF and plerixafor-mobilized cells demonstrated long-term reconstitution of multiple T- and B-cell lineages in peripheral blood, lymph node, and rectal mucosa in rhesus macaques. Representative dot plots from a control (RC808) and G-CSF and plerixafor-treated animal (RQ7375) showing EGFP expression in (A) CD3⁺CD4⁺ T-cell subsets (B) CD3⁺CD8⁺ T-cell subsets and (C) CD3⁻CD20⁺ B-cell subsets from peripheral blood 155 days post-transplant. (D) %EGFP expressing subsets of CD4⁺ and CD8⁺ T cells from peripheral blood (n = 3), lymph node (n = 3), and rectal mucosa (n = 3) collected at day 232 (RQ7424), 155 (RQ7375), and 173 (RQ7277) post-transplantation. (E) %EGFP expressing subsets of B cells from peripheral blood (n = 3), lymph node (n = 3), and rectal mucosa (n = 2) collected at day 232 (RQ7424), 155 (RQ7375), and 173 (RQ7277) post-transplantation.

(Fig. 7C). Fifty-five days post-transplantation, clumping of RBCs was observed in vitro at room temperature, but not at 37°C. Direct antiglobulin testing revealed that the animal's RBCs were coated with complement (C3d) but not

immunoglobulin G (IgG). Serological evaluation revealed an IgM cold agglutinin with a titer of 1:640 when tested against rhesus macaque control RBCs. Antibody screening revealed that the serum was reactive at immediate spin

Figure 6. Correlation between *in vitro* and *in vivo* transduction rates. We evaluated the ratio of %EGFP in the immunoselected CD34⁺ cells of the graft to %EGFP of circulating lymphocytes at 1 month, 3 months, and 6 months post-transplantation. In G-CSF and SCF-mobilized animals ($n = 5$), there was a significant linear correlation of %EGFP among *in vitro* CD34⁺ cells in the graft and *in vivo* circulating lymphocytes at all three time points ($p < 0.01$). (The regression line and 90% confidence intervals (shaded areas) are shown for the G-CSF and SCF components.) In G-CSF and plerixafor-mobilized animals ($n = 3$), a lower ratio at 1 and 3 months after transplantation was seen, compared to the ratios in the G-CSF and SCF-mobilized transplants. In contrast, the ratio was similar in both types of mobilizations at 6 months after transplantation.

(22°C) and antiglobulin (37°C) phases of testing with a panel of human adult (I-positive) group O RBCs, but was nonreactive at immediate spin and only weakly reactive, microscopically, at antiglobulin phase when tested against human adult I-negative and umbilical cord RBCs. IgG cold-reactive RBC autoantibodies were not present. Further serological testing did not detect evidence of polyagglutination or drug-induced agglutination or hemolysis using medications administered to the monkey in the pretransplant period. Serum immunoglobulin measurements (Fig. 7D), serum protein electrophoresis (Fig. 7D), and immunofixation electrophoresis (Fig. 7E) revealed elevations in serum IgG and IgM with transient appearance of corresponding paraproteins and transient disappearance of IgA levels at the time when the cold agglutinin and skin rash were apparent. By day 79, both the skin rash and cold agglutinin had resolved. This animal had no evidence of infection when the skin rash developed or upon skin biopsy, suggesting that an autoimmune reaction initiated by cells in the graft might be occurring. Aside from the transient skin rash, cold agglutinin disorder, and serum paraproteins in

one of the three transplanted animals, no other complications were observed.

Discussion

The CD34 antigen is the most frequently used antigen for identifying human HSCs [10,18,19], and cells expressing this antigen contain both HSCs and committed progenitors. In this work, we found that G-CSF and plerixafor mobilized higher numbers of CD34⁺ cells, and this increase, compared with that of G-CSF and SCF mobilization in rhesus macaques [7], likely represented lymphoid progenitors, as evidenced by higher IL-3 receptor (CD123) expression and faster peripheral blood lymphocyte recovery after transplantation. This is consistent with our previous *in vitro* microarray data, which showed CD34⁺ cells isolated with either plerixafor alone or G-CSF and plerixafor had gene expression profiles predominantly associated with lymphocyte development [7].

When we followed peripheral blood reconstitution after transplantation of these two types of mobilized

Figure 7. Complication of cold agglutinin disease in one animal after G-CSF and plerixafor-mobilized cell transplantation. In the animal with the most accelerated lymphocyte recovery, RQ7375, an erythematous skin rash developed on the face, neck, and axilla 30 days after transplantation (**A**: day 49). This rash was transient and resolved by day 79 (**B**). A skin biopsy taken on day 49 revealed an acanthotic epidermis with superficial dermal edema and perivascular lymphocytic infiltrates (**C**). On day 55, clumping of RBCs at room temperature was observed. Serological evaluation revealed an IgM-mediated cold agglutinin with a titer of 640 against healthy monkey red cells. Serum immunoglobulin measurements (**D**) and serum protein electrophoresis (**D**) and IFE (**E**) revealed transient primarily oligoclonal elevations in IgG and IgM levels, and non-measurable levels of IgA (all in mg/dL). These levels returned to near pretransplantation levels after resolution of the rash and cold agglutinin disorder. In inset (**E**): anode at the top, short horizontal arrows point at oligoclonal bands in the γ -globulin region of the acid-fixed lane (ELP), and lanes G, A, M, K, and L refer to immunofixation with monospecific antibodies against human γ -, α -, and μ -immunoglobulin heavy chains and human κ and λ immunoglobulin light chains, respectively.

CD34⁺ cells, we found that lymphoid recovery after transplantation with G-CSF and plerixafor-mobilized CD34⁺ cells was accelerated. Although the exact lymphoid subpopulations involved within this more rapid recovery were not identified, this novel observation may explain

the autoimmune reaction seen in rhesus macaque RQ7375. This animal had the fastest lymphocyte recovery and developed a transient skin rash and RBC cold agglutinin associated with oligoclonal elevation in IgG and IgM immunoglobulin levels and loss of measurable IgA.

Although the pattern of anti-I reactivity found in the animal's serum during the reaction is consistent with that typically seen in human idiopathic cold agglutinin disease, this disease in nonhuman primates has not been reported before, and this animal did not have the hemolytic anemia that is usually seen in humans. The rash and cold agglutinin were transient and disappeared when IgM and IgG levels decreased to baseline and IgA reappeared. The relationship of this transient autoimmune dysregulated immunoglobulin expression to the use of G-CSF and plerixafor-mobilized CD34⁺ cells remains speculative.

We also provided clear evidence for the first time that G-CSF and plerixafor-mobilized CD34⁺ cells contain an HSC population capable of reconstituting multilineage hematopoietic cells by lentiviral gene marking. These results corroborate and expand upon our earlier studies using plerixafor alone to mobilize and transplant HSCs in rhesus macaques [20]. In the current study, we used an EGFP-expressing χ HIV vector optimized for transduction of rhesus CD34⁺ cells [8] to mark and follow the reconstitution of G-CSF and plerixafor-mobilized CD34⁺ cells. In rhesus gene transfer preclinical studies as well as human gene therapy trials, transgene expression rates among peripheral blood cells generally fluctuate for the first few months after transplantation, then plateau at low levels approximately 6 months after transplantation [8,21,22]. One explanation for this observation is that committed progenitor cells contribute to the reconstitution of circulating blood cells in the first few months and stem cells contribute significantly later. In this study, three rhesus macaques showed long-term (1–2 years) reconstitution of multiple lineage blood cells that contained EGFP⁺ cells originating from the G-CSF and plerixafor-mobilized CD34⁺ cells and confirmed that HSCs are included in this CD34⁺ cell population. The proportion of CD34⁺ progenitors to HSCs, however, appears to be higher within the G-CSF and plerixafor-mobilized than with other mobilization regimens based on the reconstitution data.

We were initially surprised that G-CSF and plerixafor-mobilized CD34⁺ cells had reduced in vitro transduction efficiency (Fig. 1B) and lower in vivo %EGFP (Fig. 6). This observation occurred even when we used a chimeric vector that was constructed specifically for rhesus CD34⁺ cells [8]. This reduced transgene expression may have resulted from higher number of lymphocytes and lymphoid progenitors in the mobilized graft because the specific conditions required for efficient gene transfer to lymphocytes (e.g., CD3 antibody and IL-2) were not present [23]. Other possible explanations include an alteration in the CD34⁺ progenitor to stem cell ratio, which may have increased signaling via cascades that block efficient transduction; or a higher number of plasmacytoid dendritic cell precursors may have been mobilized, which were resistant to transduction [24].

In summary, G-CSF and plerixafor mobilization increased CD34⁺ cell yields by apheresis. This population

of CD34⁺ cells appears to contain more lymphoid progenitors and a similar number of HSCs capable of long-term reconstitution and stable multilineage transgene expression in vivo. The lymphoid progenitors within the CD34⁺ cell population accelerated lymphoid recovery. These findings should be helpful in developing plerixafor-based mobilization protocols in HSC transplantation studies.

Acknowledgments

This work was supported by the intramural research programs of the National Heart, Lung, and Blood Institute, the National Institute of Diabetes, Digestive, and Kidney Diseases, and the Clinical Center at the National Institutes of Health, and in part by grants, AI07812 from National Institutes of Allergy and Infectious Diseases and DE018339 and DE019397 from the National Institute of Dental and Craniofacial Research to J.J.M. We thank the staff at 5 Research Court for their excellent care and handling of the rhesus macaques. We particularly would like to thank Earl West for being the first to identify the development of the cold agglutinin in RQ7375 and Dr. Chyi-Chia Richard Lee of the Dermatopathology & Surgical Pathology of the National Cancer Institute for interpreting the skin biopsy. We would also like to thank William DeGraff and Dr. Jim Mitchell of the Radiation Biology Branch, NCI for the use of the Eldorado Cobalt-60 irradiator, and Dr. Derek Persons of the St Jude Children's Research Hospital for providing us viral vectors and sharing data.

Conflict of interest disclosure

No financial interest/relationships with financial interest relating to the topic of this article have been declared.

References

1. Copelan EA. Hematopoietic stem-cell transplantation. *N Engl J Med*. 2006;354:1813–1826.
2. Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. *N Engl J Med*. 2009; 360:447–458.
3. Gratwohl A, Wodnar-Filipowicz A. A freeway to stem cells? *Blood*. 2008;112:923–924.
4. Hematti P, Tuchman S, Larochelle A, Metzger ME, Donahue RE, Tisdale JF. Comparison of retroviral transduction efficiency in CD34⁺ cells derived from bone marrow versus G-CSF-mobilized or G-CSF plus stem cell factor-mobilized peripheral blood in nonhuman primates. *Stem Cells*. 2004;22:1062–1069.
5. Donahue RE, Kirby MR, Metzger ME, Agricola BA, Sellers SE, Cullis HM. Peripheral blood CD34⁺ cells differ from bone marrow CD34⁺ cells in Thy-1 expression and cell cycle status in nonhuman primates mobilized or not mobilized with granulocyte colony-stimulating factor and/or stem cell factor. *Blood*. 1996;87:1644–1653.
6. Donahue RE, Kuramoto K, Dunbar CE. Large animal models for stem and progenitor cell analysis. *Curr Protoc Immunol*; 2005; Chapter 22: Unit 22A 21.
7. Donahue RE, Jin P, Bonifacio AC, et al. Plerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF) mobilize different CD34⁺ cell populations based on global gene and microRNA expression signatures. *Blood*. 2009;114:2530–2541.

8. Uchida N, Washington KN, Hayakawa J, et al. Development of a human immunodeficiency virus type 1-based lentiviral vector that allows efficient transduction of both human and rhesus blood cells. *J Virol*. 2009;83:9854–9862.
9. Kootstra NA, Munk C, Tonnu N, Landau NR, Verma IM. Abrogation of postentry restriction of HIV-1-based lentiviral vector transduction in simian cells. *Proc Natl Acad Sci U S A*. 2003;100:1298–1303.
10. Uchida N, Washington KN, Lap CJ, Hsieh MM, Tisdale JF. Chicken HS4 insulators have minimal barrier function among progeny of human hematopoietic cells transduced with an HIV1-based lentiviral vector. *Mol Ther*. 2011;19:133–139.
11. Uchida N, Hanawa H, Dan K, Inokuchi K, Shimada T. Leukemogenesis of b2a2-type p210 BCR/ABL in a bone marrow transplantation mouse model using a lentiviral vector. *J Nippon Med Sch*. 2009;76:134–147.
12. Hanawa H, Persons DA, Nienhuis AW. High-level erythroid lineage-directed gene expression using globin gene regulatory elements after lentiviral vector-mediated gene transfer into primitive human and murine hematopoietic cells. *Hum Gene Ther*. 2002;13:2007–2016.
13. Hanawa H, Kelly PF, Nathwani AC, et al. Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitive hematopoietic cells from human blood. *Mol Ther*. 2002;5:242–251.
14. Mattapallil JJ, Douek DC, Hill B, Nishimura Y, Martin M, Roederer M. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. *Nature*. 2005;434:1093–1097.
15. Kader M, Hassan WM, Eberly M, et al. Antiretroviral therapy prior to acute viral replication preserves CD4 T cells in the periphery but not in rectal mucosa during acute simian immunodeficiency virus infection. *J Virol*. 2008;82:11467–11471.
16. Eberly MD, Kader M, Hassan W, et al. Increased IL-15 production is associated with higher susceptibility of memory CD4 T cells to simian immunodeficiency virus during acute infection. *J Immunol*. 2009;182:1439–1448.
17. Huang S, Chen Z, Yu JF, et al. Correlation between IL-3 receptor expression and growth potential of human CD34+ hematopoietic cells from different tissues. *Stem Cells*. 1999;17:265–272.
18. Guo Y, Lubbert M, Engelhardt M. CD34- hematopoietic stem cells: current concepts and controversies. *Stem Cells*. 2003;21:15–20.
19. Bonnet D. Haematopoietic stem cells. *J Pathol*. 2002;197:430–440.
20. Larochelle A, Krouse A, Metzger M, et al. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. *Blood*. 2006;107:3772–3778.
21. Kang EM, Choi U, Theobald N, et al. Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils. *Blood*. 115:783–791.
22. Kim YJ, Kim YS, Larochelle A, et al. Sustained high-level polyclonal hematopoietic marking and transgene expression 4 years after autologous transplantation of rhesus macaques with SIV lentiviral vector-transduced CD34+ cells. *Blood*. 2009;113:5434–5443.
23. Heim DA, Hanazono Y, Giri N, et al. Introduction of a xenogeneic gene via hematopoietic stem cells leads to specific tolerance in a rhesus monkey model. *Mol Ther*. 2000;1:533–544.
24. Rettig MP, McFarland K, Ritchey J, et al. Preferential mobilization of CD34+ plasmacytoid dendritic cell precursors by plerixafor (abstract 32). *Blood*. 2009;114.